Issue Date: August 27, 2012
Molecular Partners, Allergan Form Pacts
Molecular Partners and Allergan have two new agreements to discover and develop products for ophthalmic diseases. Allergan will pay the Swiss biotech firm $62.5 million up front and up to $1.4 billion in milestone payments. Molecular Partners develops small-protein drug candidates it calls DARPins. It will design a dual anti-VEGF-A/PDGF-B DARPin and related candidates for treating exudative age-related macular degeneration. The partners also will collaborate on finding DARPins against other eye-disease targets.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society